Expertise in
53
conditions

Dr. Mandy D. Robertson

Oncology | Hematology | Hematology Oncology
Mid-Columbia Medical Center
1700 E 19th St, 
The Dalles, OR 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
53
conditions
Mid-Columbia Medical Center
1700 E 19th St, 
The Dalles, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mandy Robertson is an Oncologist and a Hematologist in The Dalles, Oregon. Dr. Robertson is highly rated in 53 conditions, according to our data. Her top areas of expertise are Intraductal Papilloma, Pleuropulmonary Blastoma, Follicular Lymphoma, and Breast Cancer. Dr. Robertson is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Florida College Of Medicine
Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Klickitat Valley Hospital
Mid-Columbia Medical Center
Enloe Health
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

MID-COLUMBIA MEDICAL CENTER
1700 E 19th St, The Dalles, OR 97058

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Recruiting
Publish Date: April 02, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Other, Procedure
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 7 Less Clinical Trials

1 Total Publications

Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Journal: Clinical colorectal cancer
Published: June 06, 2019
Similar Doctors
Expertise in
11
conditions
Dr. Eric C. Anderson
Hematology Oncology | Oncology | Hematology
Expertise in
11
conditions
Dr. Eric C. Anderson
Hematology Oncology | Oncology | Hematology

Providence Health And Services Oregon

810 12th St, 
Hood River, OR 
 (19.1 mi)
541-387-6138
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric Anderson is a Hematologist Oncology specialist and an Oncologist in Hood River, Oregon. Dr. Anderson is highly rated in 11 conditions, according to our data. His top areas of expertise are Familial Pancreatic Cancer, Anal Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Anderson is currently accepting new patients.

Expertise in
10
conditions
Dr. Eric D. Bernstein
Oncology | Hematology Oncology
Expertise in
10
conditions
Dr. Eric D. Bernstein
Oncology | Hematology Oncology
810 12th St, 
Hood River, OR 
 (19.1 mi)
541-387-1338
Languages Spoken:
English

Eric Bernstein is an Oncologist and a Hematologist Oncology provider in Hood River, Oregon. Dr. Bernstein is highly rated in 10 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Robertson's expertise for a condition
ConditionClose
    View All 50 Advanced Conditions
    View All 137 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile